紫杉醇纳米制剂的研究进展  被引量:4

Research progress of paclitaxel nano-preparations

在线阅读下载全文

作  者:刘颖慧 李昆钊 代英辉[2] 王东凯[1] LIU Yinghui;LI Kunzhao;DAI Yinghui;WANG Dongkai(School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,China;School of Traditional Chinese Medicine,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区:[1]沈阳药科大学药学院,辽宁沈阳110016 [2]沈阳药科大学中药学院,辽宁沈阳110016

出  处:《中国药剂学杂志(网络版)》2022年第5期180-198,共19页Chinese Journal of Pharmaceutics:Online Edition

摘  要:目的 综述紫杉醇纳米制剂的研究现状与进展。方法 查阅近些年国内外关于紫杉醇纳米制剂研究的相关文献,并对其进行归纳、整理和总结。结果 紫杉醇作为一线抗肿瘤药物,肿瘤杀伤力强,但水溶性差限制了其应用,为克服这一局限性,达到高效递送,已开发出多种纳米载体,提高了临床疗效,降低了毒副作用。结论 紫杉醇纳米制剂的开发有效地解决了其临床应用的难题,多种新型纳米载体的开发带来了巨大效益。因此,开发出更高效、精准递送紫杉醇的纳米载体仍具有重要的临床意义及发展前景。Objective To review the research status and progress of paclitaxel nano-preparations. Methods The relevant literatures on paclitaxel nano-preparations at home and abroad in recent years were reviewed and summarized. Results As a first-line anti-tumor drug, paclitaxel has strong tumor lethality, but its application is limited by poor water solubility. In order to overcome this limitation and achieve efficient delivery, a variety of nano-carriers have been developed to improve the clinical efficacy and reduce the side effects. Conclusion The development of a variety of novel paclitaxel nano-preparations has effectively solved the problems of its clinical application and brought huge economic benefits. Therefore,the development of more efficient and accurate paclitaxel delivery nano-carriers still has important clinical significance and development prospects.

关 键 词:紫杉醇 纳米制剂 抗肿瘤 纳米载体 

分 类 号:R94[医药卫生—药剂学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象